SIGIRR: Key Regulator of Cell Growth, Differentiation and Inflammation

Target Name: SIGIRR

NCBI ID: G59307

SIGIRR

SIGIRR: Key Regulator of Cell Growth, Differentiation and Inflammation

SIGIRR (Toll/interleukin-1 receptor 8) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth, differentiation, and inflammation. It is also involved in the immune response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SIGIRR is a member of the Toll/interleukin-1 receptor family, which includes proteins that are involved in the regulation of cellular responses to threats, such as viruses and bacteria. These proteins are known as toll-like receptor proteins, or TLRs. TLRs are transmembrane proteins that are expressed in a variety of tissues throughout the body, including the skin, hair, and nervous system.

SIGIRR is a 21-kDa protein that is expressed in various tissues, including the brain, spleen, heart, and lungs. It is highly expressed in the brain, and is also found in the liver, muscle, and kidney. SIGIRR is primarily localized to the endoplasmic reticulum, which is the body's primary site for protein synthesis and folding.

SIGIRR is involved in a number of cellular processes that are important for cell growth, differentiation, and inflammation. It is a negative regulator of the F-actinin-associated protein 3 (FAP-3), which is a protein that is involved in cell -cell adhesion. SIGIRR is also involved in the regulation of the actinin-associated protein 2 (ACAP-2), which is involved in cell migration and invasion.

SIGIRR is also involved in the regulation of inflammation. It is a negative regulator of the nuclear factor kappa B (NF-kappa-B), which is a protein that is involved in the regulation of inflammation. SIGIRR is also involved in the regulation of the transcription factor binding protein 4 (TBP4), which is involved in the regulation of cell growth and differentiation.

SIGIRR has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of SIGIRR are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, SIGIRR has been shown to be involved in the regulation of the immune response, which is implicated in the development of autoimmune disorders.

SIGIRR is also a potential drug target. Studies have shown that inhibiting SIGIRR can protect against the neurotoxicity of a variety of drugs, including neurotoxins and chemotherapy drugs. Additionally, SIGIRR has been shown to be involved in the regulation of the efficacy of some antidepressants, which may make it a potential target for the development of new antidepressants.

In conclusion, SIGIRR is a protein that is involved in a number of cellular processes that are important for cell growth, differentiation, and inflammation. It is a negative regulator of the F-actinin-associated protein 3 (FAP-3), the actinin -associated protein 2 (ACAP-2), and the nuclear factor kappa B (NF-kappa-B). SIGIRR is also involved in the regulation of the immune response and has been implicated in the development of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, SIGIRR is a potential drug target and has been shown to protect against the neurotoxicity of some drugs. Further research is needed to fully understand the role of SIGIRR in

Protein Name: Single Ig And TIR Domain Containing

Functions: Acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways. Attenuates the recruitment of receptor-proximal signaling components to the TLR4 receptor, probably through an TIR-TIR domain interaction with TLR4. Through its extracellular domain interferes with the heterodimerization of Il1R1 and IL1RAP

The "SIGIRR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGIRR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets